Comparison of Candesartan vs Amlodipine Comparison of ...

More documents

Recommendations

Info

% ‐10 0 10 ‐20 ‐30 ‐40 10 Reduction of Endpoints in NIDDM with ARB Losartan (RENAAL) & Irbesartan (IDNT) ‐20 ‐16 ‐23 * * ** ‐25 ‐23 ‐23 ‐33 ‐28 ‐37 ** ** ** *** ‐8 4 2 37 Irbe vs Plac IDNT RENAAL *p
LIFE Incidence of Diabetes Mellitus – All Trials CHARM overall SCOPE ALPINE VALUE 37% 20% 24% Losartan vs atenolol Candesartan vs placebo Candesartan vs s HCZ Valsartan vs amlodipine DM developed in 8.2% with ARBs, compared with 10.5% with placebo or other agents (OR 0.73, 95% CI 0.64 to 0.84, p< 0.001)
Page 1 and 2: Comparison of Candesartan vs Amlodi
Page 3: 30 20 10 0 ‐10 ‐20 ‐30 ‐40
Page 7 and 8: m2 Change in LVVMI (g/m ) LIFE Echo
Page 9 and 10: ARBs for New-onset Atrial Fibrillat
Page 11 and 12: % New-onset AF with ARB Preventive
Page 14 and 15: Beyond BP effect of ARBs • Hi Hig
Page 16 and 17: CASE CASE-J CASE J CCandesartan d t
Page 18 and 19: Outline of the study Objectives : A
Page 20 and 21: Dosage Schedule Schedule 1 month BP
Page 22 and 23: Endpoints Primary imary Endpoints A
Page 24 and 25: Patient Characteristics Ttl Total n
Page 26 and 27: Antihypertensive Antihypertensive D
Page 28 and 29: Comparison of Cardiovascular Cardio
Page 30 and 31: Time Time-specific Time Time-specif
Page 32 and 33: Renal Renal Events Events per 1000
Page 34 and 35: CASE-J vs. VALUE
Page 36 and 37: Primary endpoint VALUE (Valsartan)
Page 38 and 39: BP reduction during studies mmHg SB
Page 40 and 41: All-cause mortality (CASE-J Primary
Page 42 and 43: New New-onset New New-onset onset D
Page 44 and 45: Conclusions Candesartan and Amlodip
Page 46 and 47: Background ACE ACE-inhibitors i hib
Page 48 and 49: Eligibility Inclusion criteria : An
Page 50 and 51: Endpoint Primary Endpoint Major Adv
Page 52 and 53: Patient Characteristics (1) Candesa
Page 54 and 55:
Medications at at Randomization Ran
Page 56 and 57:
Primary Primary Endpoint Cumulative
Page 58 and 59:
Candesartan vs vs Standard Standard
Page 60 and 61:
Subgroup Subgroup analysis analysis
Page 62 and 63:
Summary IIn comparison i with i h s
Page 64:
Conclusions Candesartan and Amlodip
Page 68 and 69:
% Isolated systolic hypertension 0
Page 70:
Predictors of new-onset atrial fibr
show all

Comparison of Candesartan vs Amlodipine Comparison of ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?